<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994990</url>
  </required_header>
  <id_info>
    <org_study_id>BOTD 001</org_study_id>
    <nct_id>NCT04994990</nct_id>
  </id_info>
  <brief_title>Effective AbobotulinumtoxinA Split Face Dose Response Study for Upper Facial Wrinkles</brief_title>
  <official_title>Effective AbobotulinumtoxinA Split Face Dose Response Study for Upper Facial Wrinkles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Bastidas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to determine if lower doses of botox than what is currently&#xD;
      recommended can give similar results to patients, at lower cost and lower risk to them.&#xD;
      Subjects will receive botox in the same areas of the upper face with standard doses on one&#xD;
      side of the face. On the other side, double the botox concentration will be administered,&#xD;
      free of charge to the participant, in order to see if the difference in concentration creates&#xD;
      a difference in wrinkle reduction and participant satisfaction over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper Face Wrinkle Severity 1 Week After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper Face Wrinkle Severity 1 Month After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper Face Wrinkle Severity 2 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper Face Wrinkle Severity 3 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper Face Wrinkle Severity 4 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction 1 Week After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction 1 Month After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction 2 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction 3 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction 4 Months After Botox Administration</measure>
    <time_frame>4 Months</time_frame>
    <description>A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rhytides</condition>
  <arm_group>
    <arm_group_label>Left Side of Face Receiving Double Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Right Side of Face Receiving Double Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbobotulinumtoxinA</intervention_name>
    <description>Half of face will receive standard dose of Botox</description>
    <arm_group_label>Left Side of Face Receiving Double Dose</arm_group_label>
    <arm_group_label>Right Side of Face Receiving Double Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbobotulinumtoxinA</intervention_name>
    <description>Half of face will receive double the standard dose of Botox</description>
    <arm_group_label>Left Side of Face Receiving Double Dose</arm_group_label>
    <arm_group_label>Right Side of Face Receiving Double Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Male or female, aged 18-65&#xD;
&#xD;
          -  In good general health as evidenced by medical history and exhibiting upper facial&#xD;
             wrinkles on physical examination&#xD;
&#xD;
          -  Agreement to adhere to Lifestyle Considerations (see section 5.3) as appropriate&#xD;
             throughout study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of aminoglycosides, curare like agents, and muscle relaxants&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known allergic reactions to components of the botox formulation and any of its&#xD;
             ingredients&#xD;
&#xD;
          -  Treatment with another botox product for the face within 4 months&#xD;
&#xD;
          -  Infections/preexisting weakness at the proposed injection sites on physical&#xD;
             examination&#xD;
&#xD;
          -  History of neuromuscular disorder, pre existing severe cardiovascular disease,&#xD;
             compromised respiratory function, severe dysphagia&#xD;
&#xD;
          -  Pediatric population, patients older than 65 since the effect of botox in terms of&#xD;
             duration and magnitude is highly variable in these age groups.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Bastidas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Bastidas, MD</last_name>
    <phone>516 497 7900</phone>
    <email>Nbastidas@northwell.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Nicholas Bastidas</investigator_full_name>
    <investigator_title>Associate Professor of Plastic Surgery</investigator_title>
  </responsible_party>
  <keyword>Botox</keyword>
  <keyword>Facial Wrinkles</keyword>
  <keyword>AbobotulinumtoxinA</keyword>
  <keyword>Cosmetic</keyword>
  <keyword>Dosage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

